Compare COLL & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLL | ULCC |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2015 | 2017 |
| Metric | COLL | ULCC |
|---|---|---|
| Price | $33.04 | $3.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | ★ $51.40 | $5.21 |
| AVG Volume (30 Days) | 454.6K | ★ 5.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | $780,567,000.00 | ★ $3,724,000,000.00 |
| Revenue This Year | $8.01 | $23.76 |
| Revenue Next Year | N/A | $11.48 |
| P/E Ratio | $19.13 | ★ N/A |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $26.35 | $2.89 |
| 52 Week High | $50.79 | $6.66 |
| Indicator | COLL | ULCC |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 47.38 |
| Support Level | $31.18 | $3.57 |
| Resistance Level | $36.22 | $4.15 |
| Average True Range (ATR) | 1.36 | 0.29 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 27.82 | 16.13 |
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.